Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal up2.700 +0.010 (+0.372%)
Others

20/11/2017 11:27

Luye Pharm biological antibody products enter clinical trial

[ET Net News Agency, 20 November 2017] Luye Pharma (02186) said biological antibody
products LY01008 (biosimilar to Avastin) and LY06006 (biosimilar to Prolia) have
respectively entered into phase III and phase I clinical trial in China.
LY01008 is a recombinant anti-VEGF humanized monoclonal antibody injection indicated for
colorectal cancer or non-small cell lung cancer. LY06006 is a recombinant anti-RANKL whole
human monoclonal antibody injection ndicated for osteoporosis among postmenopausal women,
reducing the risk of vertebral, non-vertebral and hip fractures. (HL)

Back to Others

Remark: Real time quote last updated: 25/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.